impact factor
logo
 

Small-vessel vasculitis

 

Damage assessment in adult IgA vasculitis. Cross-sectional results of a multicentre cohort


1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11

 

  1. Division of Rheumatology, Department of Internal Medicine, Marmara University, Istanbul, Turkey. gulsumoguz@hotmail.com
  2. Division of Rheumatology, Ankara Numune Education and Research Hospital, Ankara, Turkey.
  3. Division of Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey.
  4. Division of Rheumatology, Eskisehir Osmangazi University School of Medicine, Eskisehir, Turkey.
  5. Division of Rheumatology, Kocaeli University, Faculty of Medicine, Kocaeli, Turkey.
  6. Division of Rheumatology, Kocaeli University, Faculty of Medicine, Kocaeli, Turkey.
  7. Division of Rheumatology, Health Sciences University Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey.
  8. Division of Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey.
  9. Division of Rheumatology, Ankara Numune Education and Research Hospital, Ankara, Turkey.
  10. Division of Rheumatology, Department of Internal Medicine, Marmara University, Istanbul, Turkey.
  11. Division of Rheumatology, Department of Internal Medicine, Marmara University, Istanbul, Turkey.

CER12777
2020 Vol.38, N°2 ,Suppl.124
PI 0155, PF 0160
Small-vessel vasculitis

Free to view
(click on article PDF icon to read the article)

PMID: 32083544 [PubMed]

Received: 16/09/2019
Accepted : 04/11/2019
In Press: 11/02/2020
Published: 21/05/2020

Abstract

OBJECTIVES:
Immunoglobulin (Ig) A vasculitis affects children more commonly than adults and previous literature lacks any formal damage assessment. Our aim in this study is to investigate the disease course, relapse rates and prognostic factors in adult patients with IgA vasculitis and to evaluate the disease-related damage.
METHODS:
We assembled a retrospective cohort of adult IgA vasculitis from six tertiary Rheumatology Centres in Turkey. The demographics, clinical characteristics, treatment and outcomes of patients were abstracted from medical records.
RESULTS:
The study included 130 (male/female: 85/45) patients and the mean age was 42.2±17 years. Cutaneous manifestations and arthritis/arthralgia were the most common clinical manifestations. One hundred thirteen patients (86.9%) were treated with oral glucocorticoids (GC). As additional immunosuppressive (IS) agents, azathioprine was given to 44 (34.9%) and pulse cyclophosphamide to 18 (12.6%) patients. Seventy-nine patients (60%) had follow-up of median 15 (IQR 7-40) months. Twelve (15%) patients relapsed during follow-up. The mean VDI score was 0.4 in the last visit. Nineteen (24.7%) patients had at least one damage item at the end of follow-up. Most frequent damage items were renal 11 (42%), ocular 4 (15%) and cardiovascular 4 (15%).
CONCLUSIONS:
In this cohort the most frequent damage item was renal and was related to the disease itself. Damage score was higher in patients with more severe disease and treated more aggressively. Our results suggest that more effective treatment options are needed in a subgroup of patients with IgA vasculitis to prevent the damage related with the vasculitis, especially with more severe disease.

Rheumatology Article